Vaxart is a clinical-stage biotechnology company focused on the development of oral recombinant vaccines based on its proprietary oral vaccine platform. Co.'s oral vaccines are designed to generate immune responses that protect against a range of infectious diseases. Co. is developing prophylactic vaccine candidates that target infectious diseases, including SARS-CoV-2, a virus that causes coronavirus disease 2019; norovirus, a cause of acute gastro-intestinal enteritis; seasonal influenza and respiratory syncytial virus, a common cause of respiratory tract infections. Co. is also developing its therapeutic vaccine targeting cervical cancer and dysplasia caused by human papillomavirus. The VXRT stock yearly return is shown above.
The yearly return on the VXRT stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2017 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the VXRT annual return calculation with any dividends reinvested as applicable (on ex-dates).
|